Skip to main content
Premium Trial:

Request an Annual Quote

Natera: Monica Bertagnolli

Monica Bertagnolli has been appointed to the board of directors of Natera. She is a professor of surgery at Harvard Medical School and associate surgeon in the division of surgical oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. In addition, she is the CEO of Alliance Foundation Trial, a nonprofit organization that conducts international cancer clinical trials, as well as VP of the Coalition of Cancer Cooperative Groups. Bertagnolli holds an undergraduate degree in engineering from Princeton University and a medical degree from the University of Utah College of Medicine.

The Scan

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.

Acne-Linked Loci Found Through GWAS Meta-Analysis

Researchers in the European Journal of Human Genetics find new and known acne vulgaris risk loci with a genome-wide association study and meta-analysis, highlighting hair follicle- and metabolic disease-related genes.

Retina Cell Loss Reversed by Prime Editing in Mouse Model of Retinitis Pigmentosa

A team from China turns to prime editing to correct a retinitis pigmentosa-causing mutation in the PDE6b gene in a mouse model of the progressive photoreceptor loss condition in the Journal of Experimental Medicine.

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.